High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma-Reference-Cited by-同舟云学术

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Published:2022-01 Issue:1 Volume:15 Page:101290
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Kohtamäki Laura,Arjama Mariliina,Mäkelä Siru,Ianevski Philipp,Välimäki Katja,Juteau Susanna,Ilmonen Suvi,Ungureanu Daniela,Kallioniemi Olli,Murumägi Astrid,Hernberg Micaela

Funder

Academy of Finland

Sigrid Jusélius Foundation

Cancer Society of Finland

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N. Engl. J. Med.,2015

2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N. Engl. J. Med.,2015

3. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials;Hauschild;Eur J Cancer,2020

4. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;New Engl. J. Med.,2012

5. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Ascierto;Lancet Oncol.,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in Melanoma;2024-06-17

2. Targeting RAF dimers in RAS mutant tumors: From biology to clinic;Acta Pharmaceutica Sinica B;2024-05

3. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022;ACS Omega;2023-07-26

4. Deconvolution of ex-vivo drug screening data and bulk tissue expression predicts the abundance and viability of cancer cell subpopulations;2023-05-12

5. Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: from current standards to precision medicine;Current Opinion in Oncology;2022-08-26